Immuron Ltd — Regulatory Filings 2004

Feb 3, 2004

February 4th 2004

Company Announcement Office Australian Stock Exchange Ltd (ASX) 4^th Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

Please find herewith a company announcement "Anadis Wins Grant For Biodefence" for release and distribution to the market immediately.

Yours sincerely

CONOR GRAHAM Managing Director & CEO

ANADIS WINS GRANT FOR BIODEFENCE

Anadis Limited is pleased to announce that it has successfully attracted another major research grant from the Commonwealth Government. A total of \$786,500 of funding to Anadis has been approved by the Hon Peter McGauran, Minister for Science, from the highly competitive 'Innovation Access Program - International Science and Technology'.

The project: "Neutralisation of Respiratory Toxins and Pathogens", builds on Anadis technology for temporary protection against respiratory pathogens. Early work on this technology is already the subject of collaboration between Anadis and the Australian Department of Defence. The project focuses on the protective actions of antibodies due to their ability to bind and coat bacteria within the respiratory tract, and thus reduce the capacity of the bacteria to affect humans.

These protective antibodies can be prepared in a large scale from bovine colostrum, a field in which Anadis is a world leader.

The Commonwealth's "Innovation Access Program - International Science and Technology" is designed to assist Australian Science to interact with the best of international expertise in order to achieve goals of great importance to Australia.

This extra funding will enable Anadis to further interact with international researchers and manufacturers. In particular, we are pleased to announce that support and input has been offered from MARCE (the Mid-Atlantic Regional Centre of Excellence in Biodefense and Emerging Infectious Diseases) headquartered in Baltimore, USA. MARCE is a multi-campus organisation that was recently funded by the US government for US\$42 million and has input from 16 prestigious government, commercial and academic institution from around Washington DC.

The Director of MARCE, Professor Myron Levine stated: "this US-Australian collaboration is important in strengthening the biodefense efforts for both countries." This will provide the project with expertise in key areas such as scientific input from some of the world's top medical researchers, access to secure test facilities and field readiness evaluation reports.

Professor Myron Levine, Professor of Medicine and Paediatrics, in addition to being Director of MARCE, is the Director, Center for Vaccine Development, University of Maryland School of Medicine and, amongst others, sits on the NIAID (National Institute of Allergy and Infection Diseases) Blue Ribbon Panel on Bioterrorism Committee. Professor Levine has been extensively published with over 400 articles and over 85 book chapters.

Integration of the technology into future emergency and medical plans will be assisted by an advisory network, from a joint effort with expertise in defence and emergency management, public health and biotechnology both in Australia and the USA.

The respiratory technology will be supported by production techniques that Anadis has developed for other products. This ensures that mass production of the future products can be accomplished quickly and effectively in Australia.

Anadis also sees this as a spring-board for further development opportunities in civilian applications for the prevention and treatment of respiratory diseases.

Anadis CEO, Conor Graham, is excited with the scientific recognition and commercial opportunities the program will bring to the company. "This is our next step into respiratory medicine and builds on years of preliminary work, patent development and commercial alliances"

For more information please contact:

Dr. Grant Rawlin – General Manager Research & Development or. Arie Nudel - Investor Relations

Tel: +61 3 9358 6388 Fax: +61 3 9358 6399 Email: info@anadis.com.au